Charles River Laboratories International (NYSE:CRL) Sets New 1-Year High – Here’s Why

Charles River Laboratories International, Inc. (NYSE:CRL)’s share price reached a new 52-week high on Tuesday. The stock traded as high as $359.89 and last traded at $354.94, with a volume of 77,128 shares changing hands. The stock had previously closed at $357.27.

Analyst Ratings Changes

CRL has been the subject of a number of research analyst reports. Barclays lifted their price objective on shares of Charles River Laboratories International from $300.00 to $330.00 and gave the stock an “overweight” rating in a report on Friday, September 25th. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday, July 1st. JPMorgan Chase & Co. upgraded Charles River Laboratories International from a “neutral” rating to an “overweight” rating and raised their price target for the company from $180.00 to $310.00 in a research report on Thursday, August 6th. Robert W. Baird raised their price target on Charles River Laboratories International from $291.00 to $334.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. Finally, TD Cowen lifted their price target on Charles River Laboratories International from $300.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $302.33.

Charles River Laboratories International Price Performance

The company has a market capitalization of $17.03 billion, a PE ratio of -73.63, a PEG ratio of 3.23 and a beta of 1.40. The firm has a fifty day moving average of $295.70 and a two-hundred day moving average of $219.36. The company has a current ratio of 1.35, a quick ratio of 1.04 and a debt-to-equity ratio of 0.92.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%. Charles River Laboratories International’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 11.38 EPS for the current fiscal year.

Insider Activity

In related news, CEO Birgit Girshick sold 6,500 shares of Charles River Laboratories International stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at $10,080,038.70. The trade was a 15.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Victoria Creamer sold 4,179 shares of the company’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the sale, the executive vice president owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This represents a 12.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 118,169 shares of company stock valued at $35,191,216. Corporate insiders own 1.30% of the company’s stock.

Institutional Investors Weigh In On Charles River Laboratories International

Large investors have recently added to or reduced their stakes in the company. Physician Wealth Advisors Inc. increased its position in shares of Charles River Laboratories International by 127.9% in the third quarter. Physician Wealth Advisors Inc. now owns 98 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 55 shares during the period. Continuum Advisory LLC bought a new position in shares of Charles River Laboratories International during the second quarter valued at about $30,000. IFP Advisors Inc boosted its holdings in shares of Charles River Laboratories International by 182.8% during the third quarter. IFP Advisors Inc now owns 164 shares of the medical research company’s stock worth $48,000 after purchasing an additional 106 shares during the period. Compass Wealth Management LLC purchased a new stake in shares of Charles River Laboratories International during the third quarter worth about $69,000. Finally, Activest Wealth Management boosted its holdings in shares of Charles River Laboratories International by 25.9% during the third quarter. Activest Wealth Management now owns 277 shares of the medical research company’s stock worth $82,000 after purchasing an additional 57 shares during the period. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.